FULC Fulcrum Therapeutics Inc
Price (delayed)
$2.83
Market cap
$152.76M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$0.16
Enterprise value
$101.98M
Fulcrum Therapeutics is a clinical-stage biopharmaceutical company focused on improving the lives of patients with genetically defined rare diseases in areas of high unmet medical need. Fulcrum's proprietary product engine
Highlights
Fulcrum Therapeutics's net income has soared by 90% YoY and by 46% from the previous quarter
The company's EPS has surged by 90% YoY and by 45% QoQ
The equity has contracted by 6% from the previous quarter but it has grown by 3.3% YoY
Key stats
What are the main financial stats of FULC
Market
Valuations
Earnings
Shares outstanding
53.98M
Market cap
$152.76M
Enterprise value
$101.98M
Price to earnings (P/E)
N/A
Price to book (P/B)
0.63
Price to sales (P/S)
2.19
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
1.27
Revenue
$80M
Gross profit
$80M
Operating income
-$21.9M
Net income
-$9.73M
EBIT
-$9.73M
EBITDA
-$8.13M
Free cash flow
-$2.5M
Per share
Balance sheet
Liquidity
EPS
-$0.16
EPS diluted
-$0.16
Free cash flow per share
-$0.04
Book value per share
$4.51
Revenue per share
$1.29
TBVPS
$4.21
Total assets
$260.72M
Total liabilities
$17.68M
Debt
$8.63M
Equity
$243.03M
Working capital
$238.88M
Debt to equity
0.04
Current ratio
22.63
Quick ratio
22.12
Net debt/EBITDA
6.24
Margins
Efficiency
Dividend
EBITDA margin
-10.2%
Gross margin
100%
Net margin
-12.2%
Operating margin
-27.4%
Return on assets
-3.6%
Return on equity
-3.9%
Return on invested capital
-4.9%
Return on capital employed
-3.9%
Return on sales
-12.2%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
FULC stock price
How has the Fulcrum Therapeutics stock price performed over time
Intraday
2.54%
1 week
-6.29%
1 month
-21.17%
1 year
-68.8%
YTD
-39.79%
QTD
-1.74%
Financial performance
How have Fulcrum Therapeutics's revenue and profit performed over time
Revenue
$80M
Gross profit
$80M
Operating income
-$21.9M
Net income
-$9.73M
Gross margin
100%
Net margin
-12.2%
The net margin has soared by 100% YoY and by 45% from the previous quarter
Fulcrum Therapeutics's operating margin has soared by 99% YoY and by 27% from the previous quarter
Fulcrum Therapeutics's net income has soared by 90% YoY and by 46% from the previous quarter
The company's operating income has surged by 80% YoY and by 28% QoQ
Growth
What is Fulcrum Therapeutics's growth rate over time
Valuation
What is Fulcrum Therapeutics stock price valuation
P/E
N/A
P/B
0.63
P/S
2.19
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
1.27
The company's EPS has surged by 90% YoY and by 45% QoQ
FULC's P/B is 72% below its 5-year quarterly average of 2.2 and 59% below its last 4 quarters average of 1.5
The equity has contracted by 6% from the previous quarter but it has grown by 3.3% YoY
The price to sales (P/S) is 96% lower than the last 4 quarters average of 61.1 and 96% lower than the 5-year quarterly average of 60.1
Efficiency
How efficient is Fulcrum Therapeutics business performance
The company's return on sales has surged by 100% YoY and by 45% QoQ
Fulcrum Therapeutics's ROE has soared by 89% YoY and by 47% from the previous quarter
Fulcrum Therapeutics's ROA has soared by 89% YoY and by 46% from the previous quarter
FULC's return on invested capital has surged by 87% year-on-year and by 44% since the previous quarter
Dividends
What is FULC's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for FULC.
Financial health
How did Fulcrum Therapeutics financials performed over time
The current ratio has grown by 28% year-on-year and by 23% since the previous quarter
Fulcrum Therapeutics's quick ratio has increased by 27% YoY and by 22% from the previous quarter
The debt is 96% less than the equity
The debt has contracted by 20% YoY and by 6% from the previous quarter
The debt to equity is down by 20% year-on-year
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.